Physician profile
Nader Moaven
NPI 1831293174
$14,883.15
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,554 · 2020: $5,379 · 2021: $654 · 2022: $189 · 2023: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,383.76 | 2019-2023 | |
| Glaxosmithkline, LLC. | $492.95 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Viiv Healthcare Company | $411.50 | 2019-2023 | Dovato |
| Amarin Pharma, INC. | $247.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $199.81 | 2019-2021 | |
| Nuvasive, INC. | $198.78 | 2019 | |
| Novo Nordisk INC | $178.58 | 2019-2021 | |
| Medtronic Vascular, INC. | $117.82 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $89.24 | 2019-2023 | Farxiga |
| Horizon Therapeutics Plc | $78.75 | 2019-2021 | |
| Abbvie INC. | $74.66 | 2020-2021 | |
| Amgen INC. | $55.71 | 2019-2021 | |
| Pfizer INC. | $47.93 | 2019-2020 | |
| Napo Pharmaceuticals INC | $43.61 | 2020 | |
| Avanir Pharmaceuticals, INC. | $43.60 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.57 | 2020 | |
| Allergan, INC. | $40.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.81 | 2020-2021 | |
| Lilly USA, LLC | $24.53 | 2019-2021 | |
| Medtronic Minimed, INC. | $15.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.73 | 2019 | |
| Seqirus USA INC | $12.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Moaven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.